False nonresponders to anti‐calcitonin gene‐related peptide monoclonal antibodies: A real‐world analysis beyond migraine frequency reduction
A substantial proportion of patients with migraine classified as nonresponders to anti-CGRP MAbs at 6 months show measurable improvements beyond frequency reduction. These "false nonresponders" may benefit from continued treatment, highlighting the need for a more comprehensive assessment that includes intensity, analgesic use, disability, and quality of life to prevent premature discontinuation of potentially effective therapies. Conversely, patients with a worse baseline profile and limited early improvement may be appropriately identified as true nonresponders, justifying early treatment discontinuation.
Authors
- Mariano Huerta Villanueva (ORCID: https://orcid.org/0000-0003-0181-5335)
- Sergio Campoy (ORCID: https://orcid.org/0000-0002-8135-4139)
- Jaume Campdelacreu (ORCID: https://orcid.org/0000-0001-9196-7601)
- Joan Prat
- Albert Muñoz‐Vendrell (ORCID: https://orcid.org/0000-0001-8221-865X)
- Jordi Sanahuja
- Lidia Termens
- Patricia Díaz‐Corta (ORCID: https://orcid.org/0009-0005-5495-690X)
Institutions
- Bellvitge University Hospital (ES)
- Hospital Universitari Arnau de Vilanova (ES)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Hospital de Viladecans (ES)
- Hospital Arnau de Vilanova (ES)
Publication Details
- Journal
- Headache The Journal of Head and Face Pain
- Published
- 2025-11-28
- DOI
- https://doi.org/10.1111/head.70012
- Citations
- 1
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47